Humacyte, Inc. (HUMA)

Over the past six months, Humacyte's stock price has experienced significant fluctuations. In October 2025, Humacyte announced a $60 million registered direct offering, which led to a 17% decline in the stock price. In March 2024, the company received approximately $43.0 million in net proceeds from an underwritten public offering of its common stock and $20 million from a funding arrangement with Oberland Capital Management. In February 2024, the FDA accepted and granted Priority Review to Humacyte's BLA for the HAV in urgent arterial repair following extremity vascular trauma. At its Annual Meeting on June 10, 2025, stockholders approved an amendment to increase the number of authorized shares of common stock from 250 million to 350 million.

The provided search results do not contain explicit information about the demand seasonality for Humacyte, Inc.'s products and services. Demand would primarily be driven by clinical trial progress, regulatory approvals, and eventual market adoption rather than typical seasonal consumer patterns. The nature of its products suggests that demand, once approved, would be based on medical need rather than seasonal variations.

Humacyte, Inc. is a clinical-stage biotechnology company focused on developing and manufacturing universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems. The company aims to improve patients' lives and transform medicine by creating off-the-shelf, regenerative human acellular vessels (HAVs) designed to be implanted without inducing a foreign body response or immune rejection. Humacyte operates within the biotechnology sector, specifically in the regenerative medicine and cardiovascular surgery industries, utilizing its proprietary scientific technology platform to engineer and manufacture HAVs. The company's major product candidates, a portfolio of HAVs, are currently in late-stage clinical trials for vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease (PAD). Preclinical development is also underway for other applications, including coronary artery bypass grafts, pediatric heart surgery, and the treatment of Type 1 diabetes, as well as other novel cell and tissue applications.

Humacyte, Inc. is headquartered in Durham, North Carolina, where it also has manufacturing facilities. The company has ongoing clinical programs and partnerships that extend into Europe and North America.

Humacyte has received a consensus rating of "Moderate Buy" from analysts, with a significant upside from its current price. However, TipRanks' AI Analyst rates HUMA as "Neutral," highlighting significant financial and technical challenges. Events that have affected Humacyte's reputation include share dilution concerns from the $60 million registered direct offering, the FDA granting Priority Review to Humacyte's BLA for vascular trauma, and the company's financial performance.

As of December 2025, 29 institutional investors held positions in Humacyte, Inc. Major institutional owners include Fresenius Medical Care AG, BlackRock, Inc., The Vanguard Group, Inc., Geode Capital Management, LLC, and State Street Global Advisors, Inc. Gavril Yushvaev is a significant individual shareholder, and insiders hold 5.10% of the stock.